Antitumor activity of cis-diamminedichloroplatinum (II) depends on its time x concentration product against human gastric cancer cell lines in vitro
- PMID: 8551732
- DOI: 10.1002/jso.2930600405
Antitumor activity of cis-diamminedichloroplatinum (II) depends on its time x concentration product against human gastric cancer cell lines in vitro
Abstract
A pharmacodynamic study of cisplatin (DDP) was conducted using the gastric cancer cell lines MKN-45 and MKN-74 in vitro. Ten thousand tumor cells were incubated with 0.4-500 micrograms/ml DDP for 1-25 h, followed by recovery culture for a further 48 h. At the end of incubation, cell viability was detected by the MTT end-point, and the inhibition rate was compared in relation to the incubation time, DDP concentration, and the time X concentration product (area under the curve in vitro: AUC vitro). In both of the cell lines, the IC50 and IC90 values decreased as the exposure time increased, going a linear curve with a slope of almost -1, and showing a typical log-log AUC vitro-dependent curve. These results indicate that the antitumor activity of DDP is dependent on its AUC vitro, suggesting the clinical usefulness of this drug when administered daily in small divided doses.
Similar articles
-
Antitumour activity of cis-diamminedichloroplatinum (II) against human tumour xenografts depends on its area under the curve in nude mice.J Surg Oncol. 1996 Feb;61(2):138-42. doi: 10.1002/(SICI)1096-9098(199602)61:2<138::AID-JSO9>3.0.CO;2-D. J Surg Oncol. 1996. PMID: 8606546
-
Synergistic antitumor activity of mitomycin C and cisplatin against gastric cancer cells in vitro.J Surg Oncol. 1993 Oct;54(2):98-102. doi: 10.1002/jso.2930540209. J Surg Oncol. 1993. PMID: 8412167
-
In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).Anticancer Res. 1996 Jan-Feb;16(1):251-6. Anticancer Res. 1996. PMID: 8615617
-
Establishment of a cisplatin-resistant gastric carcinoma cell line OCUM-2M/DDP.Cancer Chemother Pharmacol. 1997;40(1):94-7. doi: 10.1007/s002800050632. Cancer Chemother Pharmacol. 1997. PMID: 9137537
-
[Intraperitoneal administration of cis-diamminedichloroplatinum (II) for peritoneal carcinomatosis caused by gastric cancers].Gan To Kagaku Ryoho. 1993 Aug;20(11):1645-8. Gan To Kagaku Ryoho. 1993. PMID: 8373238 Japanese.
Cited by
-
Modelling drug transport during intraperitoneal chemotherapy.Pleura Peritoneum. 2017 Jun 1;2(2):73-83. doi: 10.1515/pp-2017-0004. Epub 2017 Apr 14. Pleura Peritoneum. 2017. PMID: 30911635 Free PMC article. Review.
-
A mathematical model for cisplatin cellular pharmacodynamics.Neoplasia. 2003 Mar-Apr;5(2):161-9. doi: 10.1016/s1476-5586(03)80008-8. Neoplasia. 2003. PMID: 12659689 Free PMC article.
-
Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs.AAPS J. 2008;10(1):15-34. doi: 10.1208/s12248-007-9003-6. Epub 2008 Feb 5. AAPS J. 2008. PMID: 18446502 Free PMC article.
-
Enhancement of cisplatin sensitivity in Lewis Lung carcinoma by liposome-mediated delivery of a survivin mutant.J Exp Clin Cancer Res. 2010 May 12;29(1):46. doi: 10.1186/1756-9966-29-46. J Exp Clin Cancer Res. 2010. PMID: 20462440 Free PMC article.
-
Cisplatin Pharmacodynamics Following Endobronchial Ultrasound-Guided Transbronchial Needle Injection into Lung Tumors.Sci Rep. 2019 May 2;9(1):6819. doi: 10.1038/s41598-019-43270-y. Sci Rep. 2019. PMID: 31048709 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical